|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
JPS60192263A
(ja)
|
1984-03-13 |
1985-09-30 |
Teijin Ltd |
免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
CA1276103C
(en)
|
1984-10-02 |
1990-11-13 |
Fumiaki Taguchi |
Substance-conjugated complement component c1q
|
|
JPS61271455A
(ja)
|
1985-05-28 |
1986-12-01 |
Olympus Optical Co Ltd |
免疫学的分析方法
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
WO1988009344A1
(en)
|
1987-05-21 |
1988-12-01 |
Creative Biomolecules, Inc. |
Targeted multifunctional proteins
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
|
CA2115742A1
(en)
|
1991-08-20 |
1993-03-04 |
Ronald G. Crystal |
Adenovirus mediated transfer of genes to the gastrointestinal tract
|
|
EP0605522B1
(en)
|
1991-09-23 |
1999-06-23 |
Medical Research Council |
Methods for the production of humanized antibodies
|
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
JPH08503855A
(ja)
|
1992-12-03 |
1996-04-30 |
ジェンザイム・コーポレイション |
嚢胞性線維症に対する遺伝子治療
|
|
CA2115811A1
(en)
|
1993-02-17 |
1994-08-18 |
Claus Krebber |
A method for in vivo selection of ligand-binding proteins
|
|
AU687829B2
(en)
|
1993-06-24 |
1998-03-05 |
Advec, Inc. |
Adenovirus vectors for gene therapy
|
|
ATE212859T1
(de)
|
1993-09-01 |
2002-02-15 |
Sanquin Bloedvoorziening |
C1-esterasehemmer zur verringerung von myokardschäden bei akutem herzinfarkt
|
|
JP3875990B2
(ja)
|
1993-10-25 |
2007-01-31 |
カンジ，インコーポレイテッド |
組換えアデノウイルスベクターおよび使用方法
|
|
DK0796341T3
(da)
|
1994-12-09 |
1999-06-14 |
Imp College Innovations Ltd |
Identifikation af gener, som tillader tilpasning af en mikroorganisme til en særlig omgivelse
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
US5968511A
(en)
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
|
CZ137399A3
(cs)
|
1996-10-17 |
1999-07-14 |
Oxford Biomedica (Uk) Limited |
Retrovirový produkční systém pro produkci replikačně defektivních vektorovýh partikulí
|
|
GB9621680D0
(en)
|
1996-10-17 |
1996-12-11 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
GB9622500D0
(en)
|
1996-10-29 |
1997-01-08 |
Oxford Biomedica Ltd |
Therapeutic gene
|
|
US7083786B2
(en)
|
1997-04-03 |
2006-08-01 |
Jensenius Jens Chr |
MASP-2, a complement-fixing enzyme, and uses for it
|
|
US6080849A
(en)
|
1997-09-10 |
2000-06-27 |
Vion Pharmaceuticals, Inc. |
Genetically modified tumor-targeted bacteria with reduced virulence
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
ATE412431T1
(de)
|
1998-02-20 |
2008-11-15 |
Tanox Inc |
Inhibitoren der komplement-aktivierung
|
|
US6103526A
(en)
|
1998-10-08 |
2000-08-15 |
Protein Sciences Corporation |
Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
|
|
EP1152759A2
(en)
|
1999-02-09 |
2001-11-14 |
3-Dimensional Pharmaceuticals, Inc. |
METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
|
|
AU4369000A
(en)
|
1999-04-26 |
2000-11-10 |
Duke University |
Inhibition of complement action
|
|
AU6929100A
(en)
|
1999-08-23 |
2001-03-19 |
Biocrystal Limited |
Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
|
|
AU3099801A
(en)
|
2000-01-19 |
2001-07-31 |
Biotransplant Incorporated |
Swine defective for transmission of porcine endogenous retrovirus and uses thereof
|
|
DE60132169T2
(de)
|
2000-01-31 |
2008-12-11 |
Pharming Intellectual Property Bv |
Humaner c1 inhibitor hergestellt in der milch transgener säugetiere
|
|
PT1265929E
(pt)
|
2000-03-23 |
2009-10-15 |
Genentech Inc |
Inibidores anti-c2/c2a de activação complementar
|
|
AU2001282857A1
(en)
|
2000-06-21 |
2002-01-02 |
Zymogenetics Inc. |
Peptide and polypeptide inhibitors of complement c1s
|
|
ES2649037T3
(es)
|
2000-12-12 |
2018-01-09 |
Medimmune, Llc |
Moléculas con semividas prolongadas, composiciones y usos de las mismas
|
|
GB0105924D0
(en)
|
2001-03-09 |
2001-04-25 |
Microscience Ltd |
Promoter
|
|
EP1416962A4
(en)
|
2001-07-26 |
2006-05-24 |
Alexion Pharma Inc |
METHOD FOR IMPROVING THE COGNITIVE FUNCTION
|
|
EP1572893B1
(en)
|
2001-11-09 |
2009-01-07 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Production of adeno-associated virus in insect cells
|
|
JP2005515782A
(ja)
|
2002-01-11 |
2005-06-02 |
ジーティーシー バイオセラピューティックス インコーポレイテッド |
再構築された胚へ核を移植した後の融合および活性化のための方法およびシステム
|
|
US20080206242A1
(en)
|
2002-03-01 |
2008-08-28 |
Xencor, Inc. |
Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
|
|
US7657380B2
(en)
|
2003-12-04 |
2010-02-02 |
Xencor, Inc. |
Methods of generating variant antibodies with increased host string content
|
|
SE0202880D0
(sv)
|
2002-07-26 |
2002-09-30 |
Wieslab Ab |
Complement system deficiency assay
|
|
US7666627B2
(en)
|
2002-08-08 |
2010-02-23 |
Targetex Kft. |
Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
CA2496834C
(en)
|
2002-09-06 |
2014-03-18 |
Alexion Pharmaceuticals, Inc. |
Method of treatment of asthma using antibodies to complement component c5
|
|
US7361339B2
(en)
|
2003-01-09 |
2008-04-22 |
Alexion Pharmaceuticals, Inc. |
Methods for reducing morality associated with acute myocardial infarction
|
|
US9715692B1
(en)
|
2003-04-11 |
2017-07-25 |
Facebook, Inc. |
System for managing bids for pay-per-click search engines
|
|
CN1787741B
(zh)
|
2003-05-15 |
2011-08-17 |
唐纳士公司 |
用于预防和治疗败血症的方法与组合物
|
|
WO2005014849A2
(en)
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
|
US7482376B2
(en)
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
|
US8501705B2
(en)
|
2003-09-11 |
2013-08-06 |
The Board Of Regents Of The University Of Texas System |
Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
|
|
WO2005025509A2
(en)
|
2003-09-11 |
2005-03-24 |
Board Of Regents, The University Of Texas System |
Methods and materials for treating autoimmune diseases and conditions
|
|
WO2005035754A1
(ja)
|
2003-10-14 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
CA2885854C
(en)
*
|
2004-04-13 |
2017-02-21 |
F. Hoffmann-La Roche Ag |
Anti-p-selectin antibodies
|
|
US8840893B2
(en)
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US20060018896A1
(en)
|
2004-06-10 |
2006-01-26 |
University Of Leicester |
Methods for treating conditions associated with lectin-dependent complement activation
|
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
CA2847677C
(en)
|
2004-06-10 |
2018-05-01 |
Omeros Corporation |
Methods for treating conditions associated with masp-2 dependent complement activation
|
|
CN102746404B
(zh)
|
2004-11-12 |
2016-01-20 |
赞科股份有限公司 |
对FcRn的结合被改变的Fc变体
|
|
US8367805B2
(en)
*
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
EP1819731A4
(en)
|
2004-12-08 |
2013-02-13 |
Immunomedics Inc |
METHOD AND COMPOSITION FOR IMMUNOTHERAPY AND FOR THE DETECTION OF INFLAMMATORY AND DYSEGRATIVE IMMUNE DISEASES, INFECTION DISEASES, PATHOLOGICAL ANGIOGENESIS AND CANCER
|
|
DE602006010834D1
(de)
|
2005-03-16 |
2010-01-14 |
Janssen Pharmaceutica Nv |
Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
|
|
ES2523666T3
(es)
|
2005-05-31 |
2014-11-28 |
Board Of Regents, The University Of Texas System |
Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos
|
|
CA2654440C
(en)
|
2005-06-06 |
2013-09-03 |
Girish J. Kotwal |
Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
|
|
CN101218295B
(zh)
|
2005-07-05 |
2010-12-08 |
株式会社钟化 |
甲基丙烯酸类树脂组合物
|
|
US8124076B2
(en)
|
2005-08-18 |
2012-02-28 |
Ramot At Tel Aviv University Ltd. |
Single chain antibodies against β-amyloid peptide
|
|
AU2006304804B2
(en)
|
2005-10-21 |
2011-06-02 |
Vertex Pharmaceuticals Incorporated |
Modified proteases that inhibit complement activation
|
|
WO2007070375A2
(en)
|
2005-12-09 |
2007-06-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of synaptic maintenance
|
|
US9480658B2
(en)
|
2005-12-09 |
2016-11-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of synaptic maintenance
|
|
PL1965831T3
(pl)
|
2005-12-21 |
2011-12-30 |
Pharming Intellectual Property B V |
Zastosowanie inhibitora C1 do profilaktyki uszkodzenia niedokrwienno-reperfuzyjnego
|
|
FR2897868B1
(fr)
*
|
2006-02-24 |
2012-08-31 |
Lab Francais Du Fractionnement |
Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
|
|
AU2007223796B2
(en)
|
2006-03-08 |
2013-01-24 |
Astellas Us Llc |
Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
|
|
EP1989231B1
(en)
|
2006-03-21 |
2015-05-20 |
Genentech, Inc. |
Combinatorial therapy involving alpha5beta1 antagonists
|
|
US8512981B2
(en)
|
2006-06-21 |
2013-08-20 |
Amsterdam Molecular Therapeutics B.V. |
Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAV
|
|
EP2061810B1
(en)
|
2006-09-05 |
2014-11-12 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for the treatment of antibody mediated neuropathies
|
|
CA3154415A1
(en)
|
2006-10-10 |
2008-04-17 |
Regenesance B.V. |
Anti-sense oligonucleotide for use in facilitating axonal regeneration
|
|
US7858752B2
(en)
|
2006-12-05 |
2010-12-28 |
Abbott Laboratories |
Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
|
|
US8378138B2
(en)
|
2006-12-19 |
2013-02-19 |
The University of Hong Kong & Versitech Limited |
Synthetic ion channels
|
|
DK2148691T3
(en)
|
2007-02-05 |
2015-08-17 |
Apellis Pharmaceuticals Inc |
Compstatinanaloger for use in the treatment of inflammatory states of the respiratory system
|
|
US8192742B2
(en)
|
2007-03-23 |
2012-06-05 |
NovelMed Therapeutics |
Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
|
|
RS53595B1
(sr)
|
2007-07-16 |
2015-02-27 |
Genentech, Inc. |
Anti-cd79b antitela i imunokonjugati i metode upotrebe
|
|
AU2008299779B2
(en)
|
2007-08-03 |
2013-05-16 |
Genentech, Inc. |
Humanized anti-FGF19 antagonists and methods using same
|
|
WO2009020640A2
(en)
*
|
2007-08-08 |
2009-02-12 |
Swarmcast, Inc. |
Media player plug-in installation techniques
|
|
HRP20150279T1
(hr)
|
2007-12-26 |
2015-05-08 |
Xencor, Inc. |
Fc inaäśice s promijenjenim vezanjem na fcrn
|
|
WO2009121065A2
(en)
|
2008-03-28 |
2009-10-01 |
Apellis Ag |
Modulation and repletion/enhancement of the complement system for treatment of trauma
|
|
WO2009132058A2
(en)
|
2008-04-25 |
2009-10-29 |
Zymogenetics, Inc. |
Levels of bcma protein expression on b cells and use in diagnostic methods
|
|
CA2726845C
(en)
|
2008-06-04 |
2017-09-26 |
Macrogenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
|
US20090324585A1
(en)
|
2008-06-12 |
2009-12-31 |
The Trustees of the Leland Standford Junior University |
Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
|
|
BRPI0916668B1
(pt)
|
2008-08-05 |
2021-12-28 |
Novartis Ag |
Anticorpo monoclonal isolado, composição farmacêutica, ácido nucleico isolado e vetor
|
|
WO2010047830A2
(en)
|
2008-10-24 |
2010-04-29 |
The Scripps Research Institute |
Agents for hcv treatment
|
|
CN109045296A
(zh)
|
2008-11-10 |
2018-12-21 |
阿雷克森制药公司 |
用于治疗补体相关障碍的方法和组合物
|
|
JP5792626B2
(ja)
|
2008-12-01 |
2015-10-14 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
補体固定抗体の検出のための方法および組成物
|
|
AU2009324092A1
(en)
*
|
2008-12-03 |
2011-06-23 |
Genmab A/S |
Antibody variants having modifications in the constant region
|
|
US8401799B2
(en)
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
|
US20100291106A1
(en)
|
2009-05-06 |
2010-11-18 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c3b
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
KR20120105405A
(ko)
|
2009-06-23 |
2012-09-25 |
알렉시온 파마슈티칼스, 인코포레이티드 |
보체 단백질에 결합하는 이중특이적 항체
|
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
|
DK2488203T3
(en)
|
2009-10-16 |
2017-03-13 |
Omeros Corp |
METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
|
|
JP5851391B2
(ja)
|
2010-02-16 |
2016-02-03 |
国立大学法人京都工芸繊維大学 |
抗体固定化担体、抗体固定化担体の製造方法および当該抗体固定化担体の利用
|
|
AU2011223866B2
(en)
|
2010-03-01 |
2015-05-21 |
Alexion Pharmaceuticals Inc. |
Methods and compositions for treating Degos' disease
|
|
US9102949B2
(en)
|
2010-04-23 |
2015-08-11 |
University Of Massachusetts |
CNS targeting AAV vectors and methods of use thereof
|
|
NZ629829A
(en)
|
2010-04-30 |
2015-11-27 |
Alexion Pharma Inc |
Anti-c5a antibodies and methods for using the antibodies
|
|
US9090674B2
(en)
|
2010-05-17 |
2015-07-28 |
The Board Of Regents Of The University Of Texas System |
Rapid isolation of monoclonal antibodies from animals
|
|
MX2012014975A
(es)
|
2010-06-22 |
2013-03-12 |
Univ Colorado Regents |
Anticuerpos al fragmento c3d de componente 3 de complemento.
|
|
US9421240B2
(en)
|
2010-06-22 |
2016-08-23 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of neuropathic pain
|
|
TWI560199B
(en)
|
2010-08-31 |
2016-12-01 |
Sanofi Sa |
Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
|
|
TW201241008A
(en)
|
2010-10-01 |
2012-10-16 |
Alexion Pharma Inc |
Polypeptides that bind to human complement component C5
|
|
US8865164B2
(en)
|
2010-11-02 |
2014-10-21 |
Kypha, Inc. |
Detecting complement activation
|
|
CA3211246A1
(en)
|
2010-12-06 |
2012-06-14 |
Seagen Inc. |
Humanized antibodies to liv-1 and use of same to treat cancer
|
|
JP6147670B2
(ja)
|
2010-12-22 |
2017-06-14 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
改善された半減期を有する修飾された抗体
|
|
KR20220044616A
(ko)
|
2011-04-08 |
2022-04-08 |
유니버시티 오브 레스터 |
Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
|
|
CA2832871C
(en)
|
2011-05-04 |
2019-01-15 |
Omeros Corporation |
Compositions for inhibiting masp-2 dependent complement activation
|
|
US9289467B2
(en)
|
2011-08-10 |
2016-03-22 |
Case Western Reserve University |
Compositions and methods for treating bone conditions
|
|
KR102022231B1
(ko)
|
2011-12-22 |
2019-09-19 |
체에스엘 베링 게엠베하 |
중추 신경계의 2차 부종을 치료하기 위한 ｃ1-억제제의 용도
|
|
JP6081699B2
(ja)
|
2011-12-28 |
2017-02-15 |
雅史 溝上 |
Ｉｌ−２８ｂの分析方法
|
|
KR102041412B1
(ko)
|
2011-12-30 |
2019-11-11 |
한미사이언스 주식회사 |
면역글로불린 Ｆｃ 단편 유도체
|
|
CN110818798A
(zh)
|
2012-10-25 |
2020-02-21 |
美国比奥维拉迪维股份有限公司 |
抗补体C1s抗体和其用途
|
|
RS63212B1
(sr)
*
|
2012-11-02 |
2022-06-30 |
Bioverativ Usa Inc |
Antikomplementna c1s antitela i njihove primene
|
|
CN105143261B
(zh)
*
|
2013-01-31 |
2021-04-09 |
首尔大学校产学协力团 |
C5抗体以及用于预防和治疗补体-相关的疾病的方法
|
|
US20140294812A1
(en)
|
2013-03-15 |
2014-10-02 |
Xencor, Inc. |
Fc variants that improve fcrn binding and/or increase antibody half-life
|
|
EP2996722A4
(en)
|
2013-05-15 |
2017-01-11 |
Annexon, Inc. |
Methods of treatment for guillain-barre syndrome
|
|
PL3725803T3
(pl)
*
|
2013-05-23 |
2022-04-04 |
Broteio Pharma B.V. |
Cząsteczki wiążące, które wiążą ludzki czynnik C2 dopełniacza i ich zastosowania
|
|
SI3019240T1
(sl)
*
|
2013-07-09 |
2024-07-31 |
Annexon, Inc. |
Protitelesa proti komplementnemu faktorju C1q in njihova uporaba
|
|
WO2015084999A1
(en)
|
2013-12-06 |
2015-06-11 |
True North Therapeutics, Inc. |
Complement component biomarker assays
|
|
BR112017007393A2
(pt)
|
2014-10-18 |
2017-12-19 |
Pfizer |
composições de anticorpo anti-il-7r
|
|
HUE061076T2
(hu)
|
2015-04-06 |
2023-05-28 |
Bioverativ Usa Inc |
Humanizált anti-C1s ellenanyagok alkalmazási eljárások
|
|
KR20180020296A
(ko)
|
2015-06-26 |
2018-02-27 |
바이오버라티브 유에스에이 인코포레이티드 |
자가면역 및 동종면역 장애를 치료하는 방법
|
|
DK3525583T3
(da)
|
2016-10-12 |
2025-10-27 |
Bioverativ Usa Inc |
Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
|
|
TW202513092A
(zh)
|
2017-03-14 |
2025-04-01 |
美商生物維瑞提夫美國公司 |
用於治療補體介導之疾病及病症之方法
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
KR20200143459A
(ko)
|
2018-04-13 |
2020-12-23 |
추가이 세이야쿠 가부시키가이샤 |
항-보체 성분 항체 및 사용 방법
|
|
WO2020081408A1
(en)
|
2018-10-18 |
2020-04-23 |
Merck Sharp & Dohme Corp. |
Formulations of anti-rsv antibodies and methods of use thereof
|
|
EP4193153A1
(en)
|
2020-08-06 |
2023-06-14 |
Bioverativ USA Inc. |
Inflammatory cytokines and fatigue in subject with a complement mediated disease
|
|
CN117241828A
(zh)
|
2021-03-31 |
2023-12-15 |
美国比奥维拉迪维股份有限公司 |
减少冷凝集素病患者的手术相关溶血
|
|
AU2023293090A1
(en)
|
2022-06-15 |
2025-01-30 |
Bioverativ Usa Inc. |
Anti-complement c1s antibody formulation
|
|
WO2023250507A1
(en)
|
2022-06-24 |
2023-12-28 |
Bioverativ Usa Inc. |
Methods for treating complement-mediated diseases
|